Graded muscle stretch or mucosal stimulation applied to the central compartment inhibited NPY release in the orad compartment where ascending contraction was measured. NPY and the Y1-receptor agonist [Leu 31 , Pro 34 ]NPY inhibited, whereas the selective Y 1-receptor antagonist BIBP 3226 augmented ascending contraction and substance P (SP) release in the orad compartment induced by muscle stretch or mucosal stimulation. Neither agonist nor antagonist had any effect on descending relaxation or VIP release in the caudad compartment. The Y2-receptor agonist NPY13-36 and antagonist BIIE 0246 had no effect on peptide release or mechanical response. The results indicate that suppression of a tonic inhibitory influence of NPY neurons on excitatory neurotransmitter release contributes substantially to the orad contractile phase of the peristaltic reflex. The effect of NPY on neurotransmitter release is mediated by Y1 receptors. enteric nervous system; tachykinins; NPY receptors; colon NEUROPEPTIDE Y (NPY) belongs to a family of closely related tyrosine (Y)-rich peptides that includes the hormonal peptides peptide YY (PYY) and pancreatic polypeptide (PP). All three peptides are 36 amino acids long and possess a characteristic tertiary structure consisting of a U-shaped polyproline helix (PP-fold) (12, 25). PYY and PP are primarily synthesized and released from endocrine cells of the gut and pancreas, respectively, whereas NPY is exclusively located in central and peripheral neurons, including neurons of the myenteric and submucosal plexi of the enteric nervous system. In most regions of the gut, NPYcontaining neurons project within the myenteric plexus and into the circular and longitudinal muscle layers. In most species, including rat, guinea pig, mouse, and human, NPY is colocalized with VIP or nitric oxide (NO) synthase in 50-70% of enteric neurons, particularly in the colon (2, 9, 21, 27, 30).
Graded muscle stretch or mucosal stimulation applied to the central compartment inhibited NPY release in the orad compartment where ascending contraction was measured. NPY and the Y1-receptor agonist [Leu 31 , Pro 34 ]NPY inhibited, whereas the selective Y 1-receptor antagonist BIBP 3226 augmented ascending contraction and substance P (SP) release in the orad compartment induced by muscle stretch or mucosal stimulation. Neither agonist nor antagonist had any effect on descending relaxation or VIP release in the caudad compartment. The Y2-receptor agonist NPY13-36 and antagonist BIIE 0246 had no effect on peptide release or mechanical response. The results indicate that suppression of a tonic inhibitory influence of NPY neurons on excitatory neurotransmitter release contributes substantially to the orad contractile phase of the peristaltic reflex. The effect of NPY on neurotransmitter release is mediated by Y1 receptors. enteric nervous system; tachykinins; NPY receptors; colon NEUROPEPTIDE Y (NPY) belongs to a family of closely related tyrosine (Y)-rich peptides that includes the hormonal peptides peptide YY (PYY) and pancreatic polypeptide (PP). All three peptides are 36 amino acids long and possess a characteristic tertiary structure consisting of a U-shaped polyproline helix (PP-fold) (12, 25) . PYY and PP are primarily synthesized and released from endocrine cells of the gut and pancreas, respectively, whereas NPY is exclusively located in central and peripheral neurons, including neurons of the myenteric and submucosal plexi of the enteric nervous system. In most regions of the gut, NPYcontaining neurons project within the myenteric plexus and into the circular and longitudinal muscle layers. In most species, including rat, guinea pig, mouse, and human, NPY is colocalized with VIP or nitric oxide (NO) synthase in 50-70% of enteric neurons, particularly in the colon (2, 9, 21, 27, 30) .
The function of NPY upon release from myenteric neurons is unknown. The pharmacological effects of NPY applied exogenously are variable: some effects are direct, and others involve stimulation or inhibition of excitatory neurotransmitter release (3, 4, 8, 9, 17, 23-26, 28, 29, 31) . These disparate effects depend on the type of receptor expressed at various neural or muscular locations. Five distinct NPY receptors (Y 1 , Y 2 , Y 4 , Y 5 , and Y 6 ) have now been cloned and characterized pharmacologically with respect to their affinities for the endogenous ligands, NPY, PYY, and PP (10, 25 (26) . Studies by Ferrier et al. (11) using RT-PCR in nerve/muscle segments of proximal rat colon have identified the expression of Y 1 and Y 4 receptors that appear to be located on enteric neurons. Similarly, immunohistochemical studies have demonstrated the presence of Y 1 receptors on cell bodies and nerve fibers of rat intestinal myenteric but not submucosal plexus neurons (24) . These studies also suggest that the location of these Y 1 receptors is likely to be a presynaptic rather than postsynaptic location. Feletou et al. (10) identified expression of Y 2 receptors also that may be located more distally in rat colon, most likely on smooth muscle cells. The latter finding is consistent with the pharmacological results in rat colonic strips (29) and isolated smooth muscle cells from guinea pig, rabbit, and human (26) .
The present study attempts to identify a physiological role for NPY and its receptors in the regulation of neuromuscular function of the gut, with particular emphasis on the regulation of intestinal peristaltic activity. Two earlier studies suggested that NPY might play a role in regulating intestinal peristaltic activity. Holzer et al. (17) showed that exogenous application of NPY to an isolated segment of guinea pig ileum inhibited ascending contraction of circular muscle initiated by aboral balloon distension. A subsequent study in guinea pig colon by Krantis and Harding (20) showed that the hormonal peptide PYY, which exhibits a pharmacological profile similar to that of NPY, inhibited peristaltic activity as measured by the rate of propulsion of fecal pellets. In the present study, we have measured the release of NPY during the ascending and descending phases of the peristaltic reflex in the rat colon and used selective Y 1 and Y 2 receptor agonists and antagonists to identify the role of NPY and NPY receptors in the regulation of the reflex. NPY release decreased during the ascending phase of the reflex. The Y 1 -receptor antagonist BIBP 3226 augmented ascending contraction and substance P (SP) release, whereas the Y 1 agonist [Leu 31 , Pro 34 ]NPY had the reverse effect. Y 1 -and Y 2 -receptor agonists or antagonists had no effect on descending relaxation. The results suggest that NPY exerts a tonic inhibitory influence on excitatory neurotransmitter release. A decrease in this influence during the ascending phase is reflected by an increase in SP release and muscle contraction.
METHODS
Measurement of peristaltic reflex in compartmented flatsheet segments of rat colon. The peristaltic reflex was measured in a three-compartment, flat-sheet preparation of rat colon as described in detail previously (15) . A 5-to 7-cm segment of mid-to distal colon was opened along the mesenteric attachment and pinned, mucosal side up, to the Sylgard base of an organ bath such that the in situ dimensions were maintained without applying additional stretch in the circular or longitudinal direction. The segment was divided into three compartments by vertical partitions sealed with vacuum grease, and 2 ml Krebs-bicarbonate medium were added to each compartment. The composition of the medium was (in mM) 118 NaCl, 4.8 KCl, 1.2 KH 2PO4, 2.5 CaCl2, 1.2 MgSO4, 25 NaH2CO3, and 11 glucose, to which was added 0.1% bovine serum albumin, 10 M amastatin, and 1 M phosphoramidon. The peristaltic reflex was initiated by stroking the mucosa with a fine brush (2-8 strokes at a rate of 1 stroke/s) and by muscle stretch applied in the radial direction with a hook and pulley assembly (2-10 g for 30 s each). Ascending contraction of circular muscle was measured in the orad peripheral compartment, and descending relaxation was measured in the caudad peripheral compartment using force-displacement transducers attached to the muscle layers. For measurement of transmitter release, muscle stretch or mucosal stimuli was applied to the central compartment five times each during a 15-min period; the medium from the central and both peripheral compartments was collected and frozen for subsequent radioimmunoassay. At the end of each experiment, the colonic segment was cut into three sections corresponding to the tissue in the three compartments, and each section was blotted dry and weighed. The tissue wet weight was then used in the normalization of the amount of neuropeptide released into each compartment during the peristaltic reflex. The mean wet weight of tissue was similar in each compartment, and the overall mean wet weight of tissue in all compartments was 147 Ϯ 8 mg. Experiments were repeated in the presence of 1 M NPY and various Y 1 and Y2 agonists and antagonists. In experiments designed to examine the role of the Y1 receptor in the noncholinergic component of the peristaltic reflex, the effects of the Y1 agonist and antagonist were reexamined in the presence of the muscarinic receptor antagonist atropine (1 M).
Measurement of SP, VIP, and NPY. SP was measured as described previously using antibody RAS 7451 (13, 15) . The limit of detection of the assay was 3 fmol/ml, and the IC 50 was 12 Ϯ 4 fmol/ml of original sample. The concentration of SP in the samples ranged from 7 to 52 fmol/ml. The antibody reacts fully with SP but does not cross-react with NPY, neurokinin A (NKA), neurokinin B, somatostatin, VIP, or [Met]enkephalin. VIP was measured as described previously using antibody RAS 7161 (14, 15) . The limit of detection of the assay was 3 fmol/ml, and the IC 50 was 22 Ϯ 8 fmol/ml of original sample. The concentration of VIP in the samples ranged from 9 to 63 fmol/ml. The antibody reacts fully with SP but does not cross-react with VIP, NPY, pituitary adenylate cyclase activating peptide (PACAP), peptide histidine isoleucine (PHI), secretin, glucagon, somatostatin, SP, or [Met]-enkephalin. NPY was measured using antibody RAS 7180. The limit of detection of the assay was 5 fmol/ml, and the IC 50 was 110 Ϯ 17 fmol/ml of original sample. The concentration of NPY in the samples ranged from 11 to 124 fmol/ml. The antibody does not cross-react with PYY, PP, NKA, SP, somatostatin, VIP, or [Met]enkephalin. For each sample, femtomoles per milliliter of neuropeptide measured by RIA were normalized to the wet weight of colonic tissue in each compartment and to the length of the collection period and expressed as femtomoles per 100 mg tissue wet weight per minute. Release during peristaltic reflex was calculated as the change in femtomoles per 100 mg per minute from release during a 15-min basal period. Student's t-test was used to assess stastically significant differences between control release and release in the presence of NPY and various receptor agonists and antagonists. 
-argininamide} was a gift from Boehringer Ingelheim Pharma (Biberach, Germany). All other chemicals and reagents were purchased from Sigma (St. Louis, MO).
RESULTS

Inhibition of NPY release during the peristaltic reflex.
Basal release of NPY into the central and both peripheral compartments was similar, ranging from 1.18 Ϯ 0.09 to 1.43 Ϯ 0.17 fmol ⅐ 100 mg wet wt Ϫ1 ⅐ min
Ϫ1
. Stimulation of the mucosa in the central compartment at 4 and 8 strokes caused, respectively, 31.3 Ϯ 6.2 (n ϭ 4; P Ͻ 0.01) and 40.9 Ϯ 5.9% (n ϭ 4; P Ͻ 0.01) decrease in basal NPY release into the orad peripheral compartment where the ascending contraction was measured, but had no effect on NPY release into the central or peripheral caudad compartment (Fig. 1) . Similarly, muscle stretch applied to the central compartment at 4 and 10 g caused, respectively, a 26.9 Ϯ 4.4 and 40.0 Ϯ 1.4% decrease in basal NPY release into the orad peripheral compartment only (Fig. 1) .
Selective inhibition of ascending contraction by NPY. As reported previously (15) , mucosal stroking and muscle stretch applied to the central compartment elicited stimulus-dependent ascending contraction in the orad compartment and descending relaxation in the caudad compartment (Fig. 2) . Addition of 1 M NPY to the orad compartment inhibited ascending contraction elicited by mucosal stroking (60.7 Ϯ 7.4% inhibition at 2 strokes to 33.1 Ϯ 14.5% inhibition at 8 strokes) or muscle stretch (66.7 Ϯ 16.7% inhibition at 2 g to 41.1 Ϯ 4.8% inhibition at 10 g; Fig. 3 ). In contrast, addition of 1 M NPY to the caudad compartment had no effect on descending relaxation elicited by mucosal stroking or muscle stretch (Table 1) . Addition of NPY to the central compartment had no effect on ascending contraction or descending relaxation elicited by either form of stimulation ( Table 2) .
Identification of the receptor type mediating the inhibitory effect of NPY on ascending contraction. Y 1 -and Y 2 -receptor agonists and antagonists were used to characterize the involvement of these receptors in the inhibitory action of NPY on ascending contraction. Addition of the preferential Y 1 -receptor agonist [Leu 31 , Pro 34 ]NPY at a concentration of 1 M to the orad compartment had a more striking inhibitory effect than NPY on ascending contraction induced by mucosal stroking or muscle stretch: inhibition ranged from 77.6 Ϯ 14.7% at 2 strokes to 61.1 Ϯ 3.2% at 8 strokes and from 77.8 Ϯ 14.7% at 2 g to 71.0 Ϯ 1.8% at 10 g (Fig. 4) . Addition of the agonists to the orad compartment had no effect on descending relaxation (data not shown). Addition of the agonist to the caudad compartment (Table 1) or the central compartment (Table 2 ) had no effect on ascending contraction or descending relaxation elicited by either form of stimulation.
Conversely, addition of the selective Y 1 -receptor antagonist BIBP 3226 (7, 31) at a concentration of 1 M Fig. 3 . Selective inhibition of ascending contraction by NPY. The peristaltic reflex was initiated by application of mucosal stimuli (2-8 strokes) or radial muscle stretch (2-10 g) to the central compartment of a 3-compartment flat-sheet preparation of rat colon. Ascending contraction and descending relaxation were measured in the orad and caudad peripheral compartments, respectively. NPY (final concentration 1 M) was added variously to the central, orad, or caudad compartments. No effect of NPY on ascending contraction or descending relaxation was detected on addition to the central or caudad compartments for the entire range of stimuli (Tables 1 and 2 ). Selective inhibition of ascending contraction was observed on addition of NPY to the orad compartment. Results were expressed as %maximal response to mucosal stimulation (0.8 Ϯ 0.1 g) or muscle stretch (0.9 Ϯ 0.1 g). Values are means Ϯ SE of 4 experiments for each modality of stimulation. to the orad compartment caused an increase in ascending contraction elicited by mucosal stroking or muscle stretch (Figs. 2 and 5) but had no effect on descending relaxation (data not shown). The increase in ascending contraction ranged from 93.3 Ϯ 19.4% at two strokes to 41.9 Ϯ 6.6% at eight strokes and from 54.3 Ϯ 1.0% at 2 g to 13.7 Ϯ 2.8% at 10 g. Addition of the antagonist to the caudad compartment (Table 1) or the central compartment (Table 2 ) had no effect on ascending contraction or descending relaxation elicited by either form of stimulation.
In contrast, addition of the selective Y 2 -receptor agonist NPY or the selective Y 2 -receptor antagonist BIIE 0246 (6, 8) to the orad, caudad, or central compartment at a concentration of 1 M had no effect on the ascending contraction and descending relaxation response elicited by mucosal stimulation or muscle stretch (Tables 1 and 2 ; Fig. 2) .
Previous studies by us (13, 15) and others (5, 18, 22) have demonstrated that the ascending contraction component of the peristaltic reflex elicited by low levels of stimulation is mediated wholly by the release of acetylcholine from motor neurons whereas the response to more intense stimuli are mediated additionally by tachykinins. In the present study, we examined the effects of the Y 1 agonist and antagonist in the , Pro 34 ]NPY to the orad compartment inhibited ascending contraction elicited by mucosal stroking (abolition at 4 strokes to 55.6 Ϯ 4.4% inhibition at 8 strokes) or muscle stretch (abolition at 4 g to 63.4 Ϯ 5.8% inhibition at 10 g) (Fig. 6) . In contrast, addition of 1 M of the Y 1 antagonist BIBP 3226 augmented the ascending contraction response elicited by mucosal stroking (108 Ϯ 10% augmentation at 4 strokes to 28.7 Ϯ 8.7% augmentation at 8 strokes) or muscle stretch (62 Ϯ 8% augmentation at 4 g to 30.9 Ϯ 5.7% augmentation at 10 g; Fig. 6 ).
Effect of Y 1 -receptor agonist and antagonist on excitatory (SP) and inhibitory (VIP) neurotransmitter release during the peristaltic reflex.
Others (1, 5, 18, 22) and we (13, 15) have previously shown that ascending contraction of circular muscle is mediated by the combined effects of ACh and the tachykinins SP and NKA, whereas descending relaxation is mediated by the combined effects of VIP, PACAP, and NO (14, 15) . In the present study, we measured SP release as a marker of excitatory neurotransmitter release during ascending contraction and VIP release as a marker of inhibitory neurotransmitter release during descending relaxation.
At a concentration of 1 M, the Y 1 -receptor agonist [Leu 31 , Pro 34 ]NPY had no effect on basal release of SP or VIP into any compartment. The agonist had no effect also on VIP release that accompanied descending relaxation elicited by mucosal stimulation or muscle stretch, but it inhibited SP release that accompanied ascending contraction elicited by mucosal stimulation or muscle stretch (Fig. 7) . SP release during ascending contraction in the absence of the Y 1 -receptor agonist was 1.6 Ϯ 0.4 and 3.0 Ϯ 0.5 fmol ⅐ 100 mg Ϫ1 ⅐ min
Ϫ1
above basal level at 4 and 8 strokes, respectively (basal SP release: 2.6 Ϯ 0.2 fmol ⅐ 100 mg Ϫ1 ⅐ min Ϫ1 ). In the presence of the agonist, SP release elicited by 4 and 8 strokes was inhibited by 61 Ϯ 7% (P Ͻ 0.01) and 42 Ϯ 5% (P Ͻ 0.01), respectively (Fig. 7) . Similarly, SP release in the absence of the agonist was 1.3 Ϯ 0.1 and 1.9 Ϯ 0.2 fmol ⅐ 100 mg Ϫ1 ⅐ min Ϫ1 above basal level at 4 and 10 g, respectively. In the presence of the Y 1 -receptor agonist, SP release elicited by 4 and 10 g was inhibited by 52 Ϯ 5 (P Ͻ 0.01) and 46 Ϯ 9% (P Ͻ 0.01), respectively (Fig. 7) . (Tables 1 and  2 ). Selective increase in ascending contraction was observed on addition of the Y1-receptor antagonist to the orad compartment. Addition of the selective Y2-receptor antagonist BIIE 0246 (final concentration 1 M) had no effect on ascending contraction or descending relaxation. Results were expressed as %maximal response to mucosal stimulation (0.8 Ϯ 0.1 g) or muscle stretch (1.1 Ϯ 0.1 g). Values are means Ϯ SE of 6 experiments for each modality of stimulation. No effect of the Y1 agonist on ascending contraction or descending relaxation was detected on addition to the central or caudad compartments for the entire range of stimuli (Tables 1 and 2 ). Selective inhibition of ascending contraction was observed on addition of the Y1-receptor agonist to the orad compartment. Addition of the selective Y2-receptor agonist NPY13-36 (final concentration 1 M) had no effect on ascending contraction or descending relaxation (Tables 1  and 2 ). Results were expressed as %maximal response to mucosal stimulation (1.0 Ϯ 0.1 g) or muscle stretch (1.1 Ϯ 0.1 g). Values are means Ϯ SE of 7 experiments for each modality of stimulation.
The effect of the Y 1 -receptor antagonist BIBP 3226 was the reverse of that of the agonist. At a concentration of 1 M, the antagonist caused a small but significant increase (18.2 Ϯ 4.3%; P Ͻ 0.025) in basal SP release but had no effect on basal VIP release. Consistent with its ability to augment ascending contraction, the antagonist increased SP release elicited by mucosal stimulation or muscle stretch in the orad compartment but had no effect on VIP release in the caudad compartment (Fig. 8) . SP release elicited by four and eight strokes was increased by 54 Ϯ 5 (P Ͻ 0.01) and 39 Ϯ 9% (P Ͻ 0.025), respectively, whereas SP release elicited by 4 and 10 g was increased by 87 Ϯ 13 (P Ͻ 0.01) and 42 Ϯ 8% (P Ͻ 0.01), respectively (Fig. 8) .
DISCUSSION
This study provides the first evidence that NPY acts as a neurotransmitter in the intestine to regulate a physiological neuromuscular reflex. NPY appears to exert a tonic inhibitory influence of cholinergic/tachykinin neurons that mediate contraction of circular smooth muscle. This tonic inhibitory influence decreases during the ascending phase of the reflex and is reflected by a decrease in NPY release and an increase in SP release, a marker of other excitatory motor neurotransmitters, such as NKA, which is cosynthesized and coreleased with SP, and ACh which is colocalized and coreleased with both of these tachykinins (18) . The inhibitory influence of NPY neurons is consistent with the established ability of NPY to inhibit ACh release in isolated nerve/muscle preparations. An earlier study by Holzer et al. (17) showed that exogenous application of NPY to an isolated segment of guinea pig small intestine inhibited ascending contraction. However, NPY release was not measured, and selective agonists or antagonists were not available then to permit analysis of the role of endogenous NPY in the regulation of the reflex.
In the present study, evidence for the functional role of NPY and identification of the Y receptor type medi- (19, 24, 28) and by molecular analysis that disclosed the presence of mRNA encoding Y 1 and Y 4 receptors (11). The affinity of NPY or PYY for Y 4 receptors, however, is very low, between 100-and 10,000-fold lower than for the natural ligand PP, which made it highly unlikely that Y 4 receptors participated in the response to NPY (12, 25 The results further imply that in the basal state, NPY exerts a tonic inhibitory restraint on excitatory motor neurons that is relieved during the ascending phase of the reflex, and that is reflected by a decrease in NPY release and an increase in the release of excitatory neurotransmitters. The pathway that leads to a decrease in the activity of NPY neurons has not been identified. One possibility is that NPY neurons are regulated by cholinergic interneurons, which control their activity and provide additional direct excitatory input to motor neurons.
There is a noteworthy parallelism between the role of NPY in regulating the ascending pathway and the role of [Met]enkephalin in regulating the descending pathways. In earlier studies (16), we showed that opioid neurons exert a tonic restraint on inhibitory VIP/ PACAP/NOS motor neurons. This restraint is relieved during the descending phase via an increase in the activity of somatostatin interneurons that synapse with these opioid neurons. Consequently, opioid agonists inhibited and opioid antagonists augmented VIP and NO release and descending relaxation.
In previous studies, others (1, 5, 18, 22) and we (13, 15) have shown that the ascending contraction is mediated by release of ACh and the tachykinins SP and NKA. ACh is released by mucosal stimulation and muscle stretch of both low and high intensity, whereas SP and NKA are coreleased by high-intensity stimulation (13) . Consequently, atropine inhibited the contractile response to low-and high-intensity stimuli, whereas tachykinin antagonists and antibodies to SP and NKA inhibited only the response to high-intensity stimuli. In the present study, the inhibitory effects of NPY and Y 1 -receptor agonists and the stimulatory effects of Y 1 -receptor antagonists were observed at all levels of stimulation, implying that NPY regulates the release of ACh and the tachykinins. Inhibition of ACh release from activated cholinergic neurons in nervemuscle preparations of the intestine and colon is a well-established pharmacological property of NPY. In the present study, atropine abolished the response to the lowest levels of mucosal stimulation and to muscle stretch, confirming that they are wholly mediated by the release of ACh. The ability of NPY and Y 1 agonists to inhibit and of Y 1 antagonist to augment these responses to low levels of stimulation indicates that the Y 1 receptor does regulate ACh release during the ascending phase of the peristaltic reflex. The ascending contraction that remained in the presence of atropine (i.e., the noncholinergic component of ascending contraction mediated by tachykinin motoneurons) was also inhibited by the Y 1 agonist and augmented by the Y 1 antagonist. These findings were directly confirmed by measurement of SP release. The ability of the Y 1 agonist and antagonists to produce the same effect in the presence and absence of atropine indicates that the Y 1 receptors are present on motor neurons that release ACh and on those that release both ACh and tachykinins. The ability of the Y 1 agonist and antagonists to produce the same effect in the presence of atropine also indicates that the regulation of SP release is mediated directly rather than indirectly through an effect on ACh release. It is important to emphasize that the physiological action of NPY depends on its access to specific pre-or postjunctional receptors located at the site of release. The present study did not identify the site of action of NPY as pre-or postjunctional, although a recent immunohistochemical study (24) suggests that Y 1 receptors are located in nerve cell bodies in the myenteric plexus as well as on nerve fibers innervating the circular muscle layer of rat small intestine. Either location is consistent with the physiological actions of NPY identified in the present study.
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